Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

Mr Mohammad Abul Qasem

22 Apr 2014 07:01

RNS Number : 1619F
Beximco Pharmaceuticals Ltd
22 April 2014
 



BEXIMCO PHARMACEUTICALS LTD.

 

 

22nd April, 2014

 

 

Mr Mohammad Abul Qasem

 

Beximco Pharmaceuticals Limited (or "the Company"; LSE-AIM: BXP) announces with sadness the death of Mohammad Abul Qasem, a Director of the Company, on 19 April 2014.

 

Ahmed Sohail Fasiur Rahman, Chairman of Beximco Pharmaceuticals, said: "The Board of Directors recall with appreciation and gratitude Mohammad Abul Qasem's contribution towards the establishment and growth of Beximco Pharmaceuticals Ltd. The Beximco Pharma Family extends their deepest sympathy and sincerest condolences to the bereaved members of his family at his sad demise."

 

 

For further information please visit www.beximco-pharma.com or enquire to:

 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.20080

 

Daniel Stewart & Company (NOMAD and Broker)

Emma Earl

James Thomas

Tel: +44 (0)20 7776 6550

 

FTI Consulting

Simon Conway/ Victoria Foster-Mitchell

Tel: +44 (0)20 3727 1000

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.

 

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIBMRTMBMTBBI
Date   Source Headline
4th Jul 20147:00 amRNSReceives GMP Approval from Taiwan FDA
1st Jul 201411:28 amRNSStock Dividend Issued and Total Voting Rights
23rd Jun 20147:00 amRNSAGM Statement
9th Jun 20147:30 amRNSMr. Mahbubul Alam
14th May 20147:00 amRNSFinancial Results for the First Quarter of 2014
12th May 20147:00 amRNSFinal Results
9th May 20147:00 amRNSAGM Notification
30th Apr 20147:01 amRNSNotification of Preliminary Results and AGM
22nd Apr 20147:01 amRNSMr Mohammad Abul Qasem
13th Mar 201410:13 amRNSBoard Changes
16th Jan 20142:15 pmRNSAppointment of Nominated Adviser
31st Oct 20137:00 amRNS3rd Quarter Results
1st Oct 201310:35 amRNSDr. Abdul Alim Khan
31st Jul 20137:00 amRNSHalf Year Results - 2013
17th Jul 20134:34 pmRNSShare Dividend and TVR
1st Jul 20134:30 pmRNSAGM Statement
16th May 20137:00 amRNSAGM Notification
15th May 20137:00 amRNS1st Quarter Results
14th May 20137:00 amRNSFinal Results
1st May 20137:00 amRNSNotification of Preliminary Results and AGM
4th Apr 20137:00 amRNSDirectorate Change
28th Feb 20137:00 amRNSAppointment of Corporate Broker
18th Feb 20135:13 pmRNSIssue of Equity: Share dividend admitted
11th Feb 20137:00 amRNSBeximco Pharma Enters EU Market
31st Oct 20127:00 amRNS3rd Quarter Results
31st Jul 20127:00 amRNSHalf Yearly Report
2nd Jul 20127:00 amRNSAGM Statement
18th May 20127:00 amRNSAGM Notification
16th May 20127:00 amRNS1st Quarter Results
14th May 20127:00 amRNSFinal Results
30th Apr 201212:17 pmRNSReplacement notice of AGM
30th Apr 20127:00 amRNSNotification of preliminary results and AGM
28th Oct 20117:00 amRNS3rd Quarter Results
29th Jul 20117:00 amRNSHalf Yearly Report
21st Jul 20117:00 amRNSEU GMP Certificate Received
7th Jul 20117:20 amRNSStock Dividend Issued
4th Jul 20117:00 amRNSAGM Statement
19th May 20117:00 amRNSNotice of AGM
13th May 20117:00 amRNS1st Quarter Results
12th May 20117:00 amRNSFinal Results
28th Apr 201112:48 pmRNSPrice Sensitive Information
12th Jan 20119:00 amRNSDirectorate Change
25th Nov 20107:00 amRNSBeximco Pharma announces change to GDR Programme
29th Oct 20107:00 amRNS3rd Quarter Results
30th Jul 20107:00 amRNSHalf Yearly Report
23rd Jun 20109:11 amRNSStock Dividend Issued
15th Jun 20109:02 amRNSAGM Statement
10th Jun 20102:37 pmRNSAnnual Financial Report
14th May 20107:00 amRNS1st Quarter Results
11th May 20107:00 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.